You are here: Industry Insights > Octapharma

News List

Octapharma puts a spotlight on the challenges of managing inhibitors in haemophilia A at the 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) prnasia
January 20, 2022
The virtual symposium held on Wednesday, February 2, 2022, at 18:00 CET, will tell the story of the Rodriguez family and their two sons with haemophilia A as they navigate the challenges of inhibitor management.
FDA Approves Octapharma’s cutaquig® 16.5% for Pediatric PI Patients, Providing Flexible Treatment Options AmericanPharmaceuticalReview
December 10, 2021
Octapharma USA announced the FDA has approved cutaquig® [Immune globulin, Subcutaneous (Human)-hipp, 16.5% Solution] for the treatment of pediatric patients age 2 and older with primary humoral immunodeficiency (PI). The FDA previously approved...
FDA Approves Octapharma’s Octagam 10% for Adult Dermatomyositis drugs
July 23, 2021
FDA has granted approval to Octapharma USA for Octagam® 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease.
FDA Approves two Octapharma Supplements americanpharmaceuticalreview
March 30, 2021
The U.S. Food and Drug Administration (FDA) has approved two Octapharma supplements to Biological License Applications (BLA).
Akron Biotech, Octapharma enter Human AB Serum global production deal pharmaceutical-technology
January 22, 2021
Akron Biotech has signed an exclusive global agreement with Switzerland-based Octapharma to produce virally inactivated Human AB Serum for the cell therapy market using the latter’s Octaplas.
Octapharma launches phase 3 superiority study for PANS pharmaceutical-business-review
September 08, 2020
Octapharma has launched a phase 3, multicenter superiority study to compare the effectiveness of PANZYGA (immune globulin intravenous, human - ifas) 10% Liquid Preparation versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome.
Octapharma USA extends funding for Covid-19 study following positive preliminary research data pharmaceutical-business-review
June 08, 2020
Following positive preliminary data, Octapharma USA is extending funding for an investigator-initiated study (IIS) focused on treating the most critical patients at the heart of the coronavirus pandemic ...
Octapharma Extends Funding for COVID-19 Study contractpharma
June 04, 2020
Study evaluating using IVIG as investigational coronavirus treatment for adults experiencing respiratory failure.
Octapharma Supports New COVID-19 Trial contractpharma
April 17, 2020
Aims to assess if Intravenous Immunoglobulin (IVIG) can halt coronavirus progression to respiratory failure.